Ruchika Goel1, Jayakanthan Kabeerdoss1, Hindhumathi Mohan1, Sumita Danda2, Visali Jayaseelan3, T Sathish Kumar4, John Jude5, Paul Bacon6, George Joseph7, Debashish Danda1. 1. Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India. 2. Department of Medical Genetics, Christian Medical College, Vellore, India. 3. Department of Biostatistics, Christian Medical College, Vellore, India. 4. Department of Child Health, Christian Medical College, Vellore, India. 5. Department of Microbiology, Christian Medical College, Vellore, India. 6. School of Immunity and Infection, College of Medicine and Dentistry, University of Birmingham, Birmingham, UK. 7. Department of Cardiology, Christian Medical College, Vellore, India.
Abstract
AIM: Disease activity assessment in Takayasu arteritis (TA) is challenging. Human leukocyte antigen E (HLA-E) is shed from endothelium into serum as a soluble molecule (sHLA-E) in response to inflammation. We aimed to study: (i) utility of sHLA-E as a biomarker of disease activity; and (ii) association of HLA-E polymorphism rs1264457 with clinical disease in Asian-Indian TA patients. MATERIALS AND METHODS: In phase-1, sHLA-E levels were estimated in sera of 50 consecutive TA patients at baseline visit and 27 healthy controls. Serial estimations were performed in 27 of them. In phase-2, DNA of 150 TA patients and 264 healthy controls were genotyped for rs1264457 polymorphism. RESULTS: At baseline visit, disease was classified as active, stable and grumbling in 23, 18 and nine patients, respectively. sHLA-E levels were higher in active TA (43; interquartile range [IQR]: 25.3-64.6) pg/mL) than stable disease (12.9; IQR: 7.6-21.6 pg/mL) (P = 0.001). At first follow-up visit, sHLA-E levels were numerically higher in active disease than stable disease (P = 0.06) but this trend was blunted at second follow-up. sHLA-E levels increased in 54% versus 25% of patients with persistently active/relapsing and persistent stable course, respectively. rs1264457 polymorphism was not associated with susceptibility to TA and did not affect sHLA-E levels. CONCLUSION: sHLA-E level is useful as a biomarker of disease activity and course in TA patients. rs1264457 polymorphism is neither associated with susceptibility nor did it influence sHLA-E levels in TA.
AIM: Disease activity assessment in Takayasu arteritis (TA) is challenging. Human leukocyte antigen E (HLA-E) is shed from endothelium into serum as a soluble molecule (sHLA-E) in response to inflammation. We aimed to study: (i) utility of sHLA-E as a biomarker of disease activity; and (ii) association of HLA-E polymorphism rs1264457 with clinical disease in Asian-Indian TA patients. MATERIALS AND METHODS: In phase-1, sHLA-E levels were estimated in sera of 50 consecutive TA patients at baseline visit and 27 healthy controls. Serial estimations were performed in 27 of them. In phase-2, DNA of 150 TA patients and 264 healthy controls were genotyped for rs1264457 polymorphism. RESULTS: At baseline visit, disease was classified as active, stable and grumbling in 23, 18 and nine patients, respectively. sHLA-E levels were higher in active TA (43; interquartile range [IQR]: 25.3-64.6) pg/mL) than stable disease (12.9; IQR: 7.6-21.6 pg/mL) (P = 0.001). At first follow-up visit, sHLA-E levels were numerically higher in active disease than stable disease (P = 0.06) but this trend was blunted at second follow-up. sHLA-E levels increased in 54% versus 25% of patients with persistently active/relapsing and persistent stable course, respectively. rs1264457 polymorphism was not associated with susceptibility to TA and did not affect sHLA-E levels. CONCLUSION:sHLA-E level is useful as a biomarker of disease activity and course in TA patients. rs1264457 polymorphism is neither associated with susceptibility nor did it influence sHLA-E levels in TA.
Authors: Leonid Kanevskiy; Sofya Erokhina; Polina Kobyzeva; Maria Streltsova; Alexander Sapozhnikov; Elena Kovalenko Journal: Int J Mol Sci Date: 2019-11-04 Impact factor: 5.923
Authors: Eun Hye Park; Eun Young Lee; Yun Jong Lee; You Jung Ha; Wan-Hee Yoo; Byoong Yong Choi; Jin Chul Paeng; Hoon Young Suh; Yeong Wook Song Journal: Rheumatol Int Date: 2018-09-18 Impact factor: 2.631